AU4723799A - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
AU4723799A
AU4723799A AU47237/99A AU4723799A AU4723799A AU 4723799 A AU4723799 A AU 4723799A AU 47237/99 A AU47237/99 A AU 47237/99A AU 4723799 A AU4723799 A AU 4723799A AU 4723799 A AU4723799 A AU 4723799A
Authority
AU
Australia
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47237/99A
Other languages
English (en)
Inventor
Stacie Marie Halbert
Evelyne Michaud
Scott Kevin Thompson
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU4723799A publication Critical patent/AU4723799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU47237/99A 1998-06-24 1999-06-24 Protease inhibitors Abandoned AU4723799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9049398P 1998-06-24 1998-06-24
US60090493 1998-06-24
PCT/US1999/014561 WO1999066925A1 (en) 1998-06-24 1999-06-24 Protease inhibitors

Publications (1)

Publication Number Publication Date
AU4723799A true AU4723799A (en) 2000-01-10

Family

ID=22223011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47237/99A Abandoned AU4723799A (en) 1998-06-24 1999-06-24 Protease inhibitors

Country Status (6)

Country Link
EP (1) EP1093367A4 (de)
JP (1) JP2002518444A (de)
AR (1) AR018915A1 (de)
AU (1) AU4723799A (de)
CA (1) CA2335876A1 (de)
WO (1) WO1999066925A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
EP1232155A4 (de) 1999-11-10 2002-11-20 Smithkline Beecham Corp Protease inhibitoren
EP1232154A4 (de) 1999-11-10 2004-06-23 Smithkline Beecham Corp Protease inhibitoren
WO2001070232A1 (en) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Protease inhibitors
EP1465862A1 (de) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl-ketoamiden derivate und ihre verwendung als cathepsin-k-inhibitoren
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
TWI359017B (en) * 2003-11-10 2012-03-01 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
UY30850A1 (es) * 2006-12-29 2008-07-31 Abbott Gmbh & Amp Compuestos carboxamida y su usos como inhibidores de calpaina
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
CN102408387A (zh) * 2010-09-26 2012-04-11 韩南银 一种具有抗肿瘤作用的金属络合物
CA2882088C (en) * 2012-08-23 2021-11-23 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN103113300A (zh) * 2013-03-06 2013-05-22 广西中医药大学 一种具有抗肿瘤活性的化合物的制备方法和用途
CN104487415B (zh) * 2013-05-08 2016-11-09 杨永亮 一种马来酰胺化合物、其制备方法及其用途
CN103242321A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 苄基哌嗪类化合物及其抗肿瘤用途
PE20160547A1 (es) 2013-08-21 2016-06-19 Alios Biopharma Inc Compuestos antivirales
CN103880702B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗白血病药物中的应用
CN103880703B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人胎盘绒毛癌药物中的应用
CN103880701B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人宫颈鳞状癌药物中的应用
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL326508A1 (en) * 1995-10-30 1998-09-28 Smithkline Beecham Corp Protease inhibitors

Also Published As

Publication number Publication date
EP1093367A4 (de) 2003-03-05
JP2002518444A (ja) 2002-06-25
AR018915A1 (es) 2001-12-12
EP1093367A1 (de) 2001-04-25
CA2335876A1 (en) 1999-12-29
WO1999066925A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
PL349192A1 (en) Protease inhibitors
AU7127298A (en) Serine protease inhibitors
IL131661A0 (en) Protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
AU4723799A (en) Protease inhibitors
AU6007200A (en) Cysteine protease inhibitors
HUP0002247A3 (en) Protease inhibitors
AU1795697A (en) Serine protease inhibitors
AU7139598A (en) Protease inhibitors
IL132630A0 (en) Protease inhibitors
AU1877597A (en) Serine protease inhibitors
ZA983522B (en) Protease inhibitors
AU9059798A (en) Urokinase inhibitors
AU4092799A (en) Protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
AU9110298A (en) Protease inhibitors
AU2723099A (en) Tryptase inhibitors
AU4229599A (en) Protease inhibitor peptides
AU1588901A (en) Protease inhibitors
AU2713100A (en) Protease inhibitors
AU4564499A (en) Protease inhibitors
AU9300298A (en) Protease inhibitors
AU1474801A (en) Protease inhibitors
AU3888200A (en) Protease inhibitors
AU1474701A (en) Protease inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase